Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whether it is effective for treating idiopathic generalised epilepsy. We compared 12-week baseline and LEV treatment periods for patients with generalised seizure types-myoclonic, tonic-clonic and absence seizures--who had failed other anticonvulsants. The majority of 55 patients (76%) had >50% seizure reduction with LEV therapy, 40% became seizure-free; 15% discontinued LEV due to adverse events, mostly sedation. This is preliminary evidence that LEV is effective for treating idiopathic generalised epilepsy
AbstractThis prospective observational study explored the efficacy and tolerability of levetiracetam...
Background Juvenile myoclonic epilepsy is the most common type of generalized idiopathic e...
SummaryPurposeTo describe our experience with levetiracetam (LEV) as initial or conversion monothera...
Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whe...
AbstractLevetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncer...
Clinical experience in open-label studies and anectodal reports suggest that levetiracetam is effect...
SummaryPurposeLevetiracetam (LEV) is a new antiepileptic drug highly effective as add-on treatment i...
AbstractLevetiracetam is highly effective as add-on treatment in refractory partial-onset seizures b...
Levetiracetam is highly effective as add-on treatment in refractory partial-onset seizures but there...
AbstractPurpose: To evaluate the efficacy of levetiracetam in cases of refractory primary generalise...
AbstractThis prospective open-label study used flexible dosing schedules of levetiracetam (LEV) in p...
Rationale: Levetiracetam (LEV) is a newantiepileptic drug (AED) indicated as adjunctive therapy in t...
SummaryPurposeTo evaluate the efficacy and tolerability of levetiracetam (LEV) as either ‘de novo’ (...
AbstractProblem: Levetiracetam (LEV) is a new antiepileptic drug shown to be effective for the treat...
Rationale: The aim of this study is to evaluate efficacy and tolerability of levetiracetam (LEV), as...
AbstractThis prospective observational study explored the efficacy and tolerability of levetiracetam...
Background Juvenile myoclonic epilepsy is the most common type of generalized idiopathic e...
SummaryPurposeTo describe our experience with levetiracetam (LEV) as initial or conversion monothera...
Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whe...
AbstractLevetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncer...
Clinical experience in open-label studies and anectodal reports suggest that levetiracetam is effect...
SummaryPurposeLevetiracetam (LEV) is a new antiepileptic drug highly effective as add-on treatment i...
AbstractLevetiracetam is highly effective as add-on treatment in refractory partial-onset seizures b...
Levetiracetam is highly effective as add-on treatment in refractory partial-onset seizures but there...
AbstractPurpose: To evaluate the efficacy of levetiracetam in cases of refractory primary generalise...
AbstractThis prospective open-label study used flexible dosing schedules of levetiracetam (LEV) in p...
Rationale: Levetiracetam (LEV) is a newantiepileptic drug (AED) indicated as adjunctive therapy in t...
SummaryPurposeTo evaluate the efficacy and tolerability of levetiracetam (LEV) as either ‘de novo’ (...
AbstractProblem: Levetiracetam (LEV) is a new antiepileptic drug shown to be effective for the treat...
Rationale: The aim of this study is to evaluate efficacy and tolerability of levetiracetam (LEV), as...
AbstractThis prospective observational study explored the efficacy and tolerability of levetiracetam...
Background Juvenile myoclonic epilepsy is the most common type of generalized idiopathic e...
SummaryPurposeTo describe our experience with levetiracetam (LEV) as initial or conversion monothera...